Spyre Therapeutics (NASDAQ: SYRE) Chief Financial Officer Scott L. Burrows carried out a pair of related equity transactions on April 1, 2026, selling 7,500 shares of the company's common stock while simultaneously exercising options to purchase 7,500 shares.
The sale produced proceeds of approximately $370,076. The disposals were executed across multiple trades at prices between $48.69 and $50.15 per share. On the same date Burrows exercised options to buy 7,500 shares at an exercise price of $14.50 per share, for a cash outlay of $108,750.
Following these moves, Burrows is reported to directly hold 97,994 shares of Spyre Therapeutics stock, a total that includes 67,476 restricted stock units.
Market context
At the time of the transactions Spyre's shares were trading at $47.58, close to a 52-week high of $51.06. The stock has risen 272% over the prior 12 months, contributing to a market capitalization of $3.74 billion. Separately, InvestingPro's analysis cited in company materials characterizes the shares as overvalued relative to its Fair Value estimate, ranking SYRE among the more overvalued names tracked by the platform.
Clinical program developments
Spyre has also announced progress across several clinical programs and adjusted timelines. Enrollment for the SPY001 antibody arm within the SKYLINE platform trial for ulcerative colitis finished ahead of schedule, enabling Part A readouts to begin in the second quarter of 2026. The company also accelerated its Phase 2 SKYWAY basket trial for rheumatoid arthritis, moving the expected topline readout from the fourth quarter of 2026 to the third quarter of 2026.
These timeline updates form the basis for recent analyst activity. Stifel raised its price target on Spyre shares to $92, citing the potential of Spyre's TL1A monoclonal antibody, SPY002, in inflammatory bowel disease. BTIG reiterated a Buy rating with a $70 price target following a co-funding agreement involving Johnson & Johnson for a new co-antibody. Leerink Partners continues to rate Spyre as Outperform, calling out the compressed trial schedules. Guggenheim reiterated Spyre as one of its top picks for 2026, also noting the faster rheumatoid arthritis timeline.
Investor resources
The company disclosure notes that InvestingPro subscribers can access 14 additional ProTips for SYRE along with expanded financial metrics and the platform's Fair Value analysis.
These transactions and program updates present a mix of insider activity and near-term clinical milestones that market participants can weigh alongside valuation assessments.